Nebius

Nebius Group N.V. · NBIS · NASDAQ

Q2 revenue rose 454.0% year over year, but a quarterly free cash flow of −$3.41B and $142.2M of net insider selling weigh on the stock ahead of the Nov 12 earnings report

Overall Verdict
SELL
Bull 1 · Bear 4 · Deferred 1

Price at Issue	External Average Target Price	52-Week Low · High	Next Earnings
$134.00	**$278.05**	**$73.52 ~ $299.86**	**Nov 12**
Nov 10, 2026 close · −5.3%	+107.5% · 20 analysts	vs. high −55.3%	Q3 2026 earnings

01 4 Key Data Points

Quarterly free cash flow −$3.41B
Q2 · capex $5.66B vs operating cash flow $2.25B · cash $8.04B

Net insider selling of $142.2M in 60 days
COO sold $117.8M on Oct 5 · stock compensation is 13.9% of revenue

Q2 revenue +454.0%, ARR $3B
$582.3M · year-end ARR target of $7–9B reaffirmed (per reports)

Two target cuts (Oct 21, Nov 4)
Piper 237→185 · Citi 324→265 · $278.05 average is 107.5% above the close

02 Research Team Debate — 6 Issues

Q3 earnings (Nov 12) ×2	보류	This event has not happened yet, so the ruling is on hold. The Nov 12 report will show Q3 revenue, ARR growth and whether the year-end target stands, and the ruling reopens on that result.
Funding	Bear	Operating cash flow includes customer prepayments (H1 deferred revenue up $4.395B, 6-K) and the 2026 capex plan is over 2.5 times cash, so more funding is needed; ruling Bear.
Insider selling	Bear	Net selling of $142.2M is above the $10M threshold and stock compensation at 13.9% of revenue is above the 10% threshold, so ruling Bear. The director's $255K of buying is about 0.2% of the selling.
Valuation	Bear	P/S of 26.9x divided by 454.0% growth is 0.06, above CoreWeave's 0.03 and 3.1 times the peer median P/S, so the stock is expensive for its growth; ruling Bear.
CoreWeave read-through	Bull	The question is whether the sector good news reaches NBIS; a rival serving the same demand reporting a backlog and demand above capacity is also supportive for NBIS, so ruling Bull. The premarket move is not yet in the close.
Target cuts	Bear	Targets are judged by the direction of recent changes. Since Oct 21 there are two cuts (−21.9%, −18.2%) and no raises, so ruling Bear despite the high average.

The overall ruling is SELL. Revenue growth and sector demand are real, but funding, executive selling, valuation and target cuts weighed more; the ruling reopens if the Nov 12 Q3 report confirms ARR and guidance.

03 Conditions That Change the Verdict

▲ Upgrade Conditions

Nov 12 Q3 earnings
Revenue at or above the $907M consensus with the $7–9B year-end ARR target reaffirmed

Funding plan
Capex funding is announced without a large equity issue

Reclaiming the 20-day average
A close above the 20-day average of $158.16

▼ Downgrade Conditions

Nov 12 Q3 earnings
Revenue below the $907M consensus or a lower year-end ARR target

Support break
A close below the Nov 5 close of $120.37 (lower Bollinger band $120.93)

More target cuts
The average target falls below $250 or a major broker moves to Sell

Sources: Company 6-K , Stocktwits and IBD , 24/7 Wall St. , search summaries · SEC EDGAR 6-K Aug 12, 2026 results report https://www.sec.gov/Archives/edgar/data/1513845/000110465926094844/nbis-20260812xex99d1.htm · Yahoo Finance · Yahoo Finance quarterly and annual

04 Quarterly Results Unit: $B

	Q2 2025	Q3	Q4	Q1 2026	Q2
Revenue	0.1	0.1	0.2	0.4	**0.6**
Operating Income	-0.1	-0.1	-0.2	-0.1	**-0.2**
Net Income	0.6	-0.1	-0.3	0.6	**-0.2**
Operating Margin	-105.8%	-89.1%	-109.8%	-32.1%	**-30.2%**


Operating margin
−30.2%
Year ago −105.8%

Net margin
−32.7%
Year ago +556.0%

Operating cash flow margin
+385.7%
Year ago −163.3%

Free cash flow margin
−585.8%
Year ago −649.1%

05 P/S trend



06 Street Opinions

Buy 15 Hold 6 Sell 1 Avg $278.05 · High $410.00 · Low $84.00

Citigroup	265	Target cut
Piper Sandler	185	Target cut
Rosenblatt	304	Initiated at Buy
BNP Paribas	399	Target raised

07 Financial Strength

Cash and short-term investments (6/30)
$8.04B
$1.68B → +378.9%

Total debt (6/30)
$10.17B
$1.22B → +730.8%

Equity (6/30)
$10.34B
$3.78B → +173.9%

Shares outstanding (6/30)
271.9M shares
239.8M shares → +13.4%

08 Recent News

11/11 NBIS reported up more than 11% premarket after CoreWeave results
Stocktwits and IBD headlines (backlog $132B, demand above capacity) · after the close, not in the price; figures below are the Nov 10 close

11/5 Down 14.9% in one day to $120.37, the lowest close since mid-August
Yahoo quotes · IREN also fell 17.0% that day · volume was 1.9 times the 20-day average

11/4 Citigroup cuts target to $265 from $324, keeps Buy
Yahoo price targets, Nov 4

09 Upcoming Events

Nov 12 (Thu) · Q3 2026 earnings (Yahoo schedule)
Consensus revenue $907M · EPS −$0.63 · ARR and guidance in focus

Nov 13 (Fri) · Weekly options expiry
Max pain $142 · put/call open interest 0.61

Nov 20 (Fri) · Options expiry
Max pain $175 · put/call open interest 0.95

10 Key Risks

Funding capex (free cash flow −$3.41B vs cash $8.04B)
Impact High · Likelihood High · Watch Nov 12 earnings

Missing the $7–9B year-end ARR target
Impact High · Likelihood High · Watch Nov 12 earnings

Reliance on customer advances (H1 deferred revenue +$4.395B) and delivery slips
Impact Medium · Likelihood High · Watch Next quarterly report

11 Checkpoints

★★★ **Nov 12 Q3 earnings**
Watch whether revenue reaches the $907M consensus and whether the $7–9B year-end ARR target holds.

★★★ **Capex funding**
Watch for new debt or equity. Cash is $8.04B and quarterly free cash flow is −$3.41B.

★★☆ **New capacity start-up schedule**
If new capacity starts on schedule from late Q4, worries about the year-end ARR target ease.